Pulmonx Corporation ( (LUNG) ) has released its Q4 earnings. Here is a breakdown of the information Pulmonx Corporation presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Pulmonx Corporation, a leader in minimally invasive treatments for chronic lung diseases, focuses on delivering innovative solutions for patients with COPD and emphysema. The company recently announced its financial results for the fourth quarter and full year of 2024, showcasing significant growth in revenue and strategic partnerships.
Pulmonx reported a 22% increase in worldwide revenue to $83.8 million for the full year 2024, with a notable 23% rise in fourth-quarter revenue to $23.8 million. U.S. revenue also saw impressive growth, highlighted by a 23% increase for the year, driven by the adoption of the Zephyr Valve procedures. Additionally, Pulmonx expanded its reach by partnering with the American Lung Association and introducing the LungTraX software in pilot U.S. sites.
The company’s gross margin remained strong at 74% for both the fourth quarter and the full year, despite an increase in operating expenses due to ongoing investments in commercial activities and clinical development. Although Pulmonx reported a net loss of $56.4 million for the year, this was an improvement from the previous year’s loss, indicating better financial management and operational efficiency.
Looking ahead, Pulmonx expects to continue its growth trajectory in 2025, with projected revenue increases and stable gross margins. The company remains committed to driving long-term sustainable growth through strategic initiatives and innovation in the treatment of lung disease.
